BCHBCH 10652

Drug Profile

BCHBCH 10652

Alternative Names: dOTC

Latest Information Update: 18 Aug 2000

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Developer Shire Pharmaceuticals Group; Wyeth
  • Class Antiretrovirals; Nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 18 Aug 2000 A study in volunteers has been added to the adverse events and pharmacokinetics sections
  • 05 May 2000 Discontinued-II for HIV infections treatment in USA (Unknown route)
  • 30 Dec 1999 A preclinical study has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top